Sign up to save your podcasts
Or
Share Alex Blyth - CEO LifT Biosciences at BIO Boston 2025
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Alex Blyth - CEO LifT Biosciences at BIO Boston 2025
From BIO Boston: Alex Blyth, CEO of LifT Biosciences
In this powerful opening episode from BIO 2025, I sit down with Alex Blyth, the founder and CEO of LifT Biosciences — a company re-engineering the immune system to finally beat cancer at its own game.
We talk about:
Why targeted therapies are failing most patients
What tumour escape is and why it’s the real enemy
How LiFt’s “super neutrophils” could be the Keytruda of innate immunity
And the personal loss that pushed Alex to rethink everything we know about cancer treatment
Alex’s story is sharp, ambitious, and deeply personal — exactly the kind of leadership biotech needs right now.
This is the first in a series of in-person interviews from BIO Boston with some of the sharpest founders and execs in the industry.
Stay tuned — more to come.
View all episodes
By Max Brennan - Biotech HeadHunterFrom BIO Boston: Alex Blyth, CEO of LifT Biosciences
In this powerful opening episode from BIO 2025, I sit down with Alex Blyth, the founder and CEO of LifT Biosciences — a company re-engineering the immune system to finally beat cancer at its own game.
We talk about:
Why targeted therapies are failing most patients
What tumour escape is and why it’s the real enemy
How LiFt’s “super neutrophils” could be the Keytruda of innate immunity
And the personal loss that pushed Alex to rethink everything we know about cancer treatment
Alex’s story is sharp, ambitious, and deeply personal — exactly the kind of leadership biotech needs right now.
This is the first in a series of in-person interviews from BIO Boston with some of the sharpest founders and execs in the industry.
Stay tuned — more to come.